Assessment of Anti‐Xa activity in patients receiving concomitant apixaban with strong p‐glycoprotein inhibitors and statins

WHAT IS KNOWN AND OBJECTIVES: Although the apixaban Food and Drug Administration (FDA) package insert recommends dose reduction in patients administered dual strong inhibitors of p‐glycoprotein (P‐gp) and cytochrome P‐450 (CYP) 3A4, there are limited published data regarding potential drug‐drug inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Milner, Erin, Ainsworth, Michael, Gleaton, Melinda, Bookstaver, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305439/
https://www.ncbi.nlm.nih.gov/pubmed/35032137
http://dx.doi.org/10.1111/jcpt.13596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305439/
https://www.ncbi.nlm.nih.gov/pubmed/35032137
http://dx.doi.org/10.1111/jcpt.13596

Ejemplares similares